COLUMBIA, Mo., March 11, 2019 /PRNewswire/ — Joseph A. Abboud, MD, Professor of Shoulder and Elbow Surgery, and Senior Vice President – Rothman Institute and Anand Murthi, MD, Chief, Shoulder and Elbow Surgery, Director of Shoulder and Elbow Fellowship and Research at MedStar Union Memorial Hospital/MedStar Orthopaedic Institute, will present ways that new intraoperative note and patient outcomes collection technologies in concert with the ShoulderJam registry can be used to assess and improve orthopedic patient outcomes and grow surgeons’ shoulder and elbow practices.
Dr. Abboud will present on Wednesday, March 13 from 11am – 11:30am. Dr. Murthi will present on Friday, March 15 from 12:30 – 1pm. Attendees to these free presentations will learn how to:
About OBERD (Universal Research Solutions, LLC)
OBERD (a.k.a. Universal Research Solutions, LLC) owns, develops, implements and supports outcomes and clinical data collection software systems. OBERD optimizes the data collection necessary to empower evidence-based medical practice, improve the quality and efficacy of care and advance clinical decision-making and patient understanding. OBERD has been collecting patient outcomes data in orthopaedics for over 7 years, with over 10 million scored forms from over 4 million patients in its database. It includes a QCDR, with CMS-approved measures specific to orthopaedics. For more information, visit www.oberd.com, email info@oberd.com or follow the company on Twitter @oberdnews.
SOURCE OBERD
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…